Anti-Obesity Drugs Market is expected to reach US$ 43.7 billion by 2030 | Major Companies - Eli Lilly and Company, Bayer AG, Bristol-Myers Squibb, F. Hoffmann-La Roche AG.

Market Size and Growth:

The Global Anti-Obesity Drugs Market size reached US$ 2.5 billion in 2022 and is expected to reach US$ 43.7 billion by 2030, growing with a CAGR of 45.5% during the forecast period 2024-2031.

The Anti-Obesity Drugs Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/anti-obesity-drugs-market?sz

The Anti-Obesity Drugs Market comprises pharmaceutical therapies designed to reduce body weight and manage obesity by suppressing appetite, enhancing satiety, or altering metabolic processes. It includes prescription medications, emerging biologics, and combination therapies, driven by rising obesity prevalence, lifestyle-related disorders, increasing healthcare awareness, and growing demand for effective, long-term weight management solutions worldwide.

Recent Key Developments of United States:

✅ December 2025: President Trump's administration launched a federal initiative partnering with pharma giants to subsidize anti-obesity drugs for low-income groups, aiming to cut obesity-related healthcare costs estimated at $200 billion annually.

✅ November 2025: Novo Nordisk announced positive Phase 3 results for an oral semaglutide formulation with higher bioavailability, targeting better patient adherence; interim data indicated up to 20% weight reduction over 68 weeks. Regulatory submission followed swiftly to capture more market share.

✅ October 2025: FDA expanded approval for Eli Lilly's tirzepatide (Zepbound) to include adolescents aged 12-17, based on successful pediatric trials showing significant weight loss. This move addresses rising youth obesity rates amid ongoing supply chain optimizations for GLP-1 drugs.

Recent Key Developments of Japan:

✅ December 2025: Fuji Keizai projected the market to hit 46.6 billion yen by 2040, driven by GLP-1 uptake; this spurred Eli Lilly's local investment in tirzepatide production facilities to meet anticipated demand surge.

✅ November 2025: Taisho Pharmaceutical expanded OTC sales of orlistat (Alli) nationwide after pilot success, marking a shift toward accessible non-prescription options amid government "Metabo Law" enforcement for waistline checks.

✅ October 2025: Japan's PMDA granted fast-track review to a novel dual GIP/GLP-1 agonist from a local biotech firm, following early trial data showing superior visceral fat reduction compared to existing therapies like liraglutide.

List of the Key Players in the Anti-Obesity Drugs Market:

Eli Lilly and Company
Bayer AG
Bristol-Myers Squibb
Currax Pharmaceuticals LLC
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Merck & Co. Inc.
Norgine BV
Novo Nordisk AS
Pfizer Inc.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/anti-obesity-drugs-market?sz

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Segments Covered in the Anti-Obesity Drugs Market:

By Mechanism of Action: Peripherally Acting Drugs, Centrally Acting Drugs.

By Drug Type: Prescription Drugs, OTC Drugs.

By Route of Administration: Oral, Intravenous/Subcutaneous.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=anti-obesity-drugs-market

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Anti-Obesity Drugs market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Anti-Obesity Drugs Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global Anti-Obesity Drugs market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Anti-Obesity Drugs Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Anti-Obesity Drugs Market in 2025?
◆ What is the projected growth rate of the Anti-Obesity Drugs Market through 2033?
◆ Who are the key players in the Anti-Obesity Drugs Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.